AngioChem

Angiochem is a clinical-stage biotechnology company discovering and developing novel breakthrough peptide drug conjugates that utilize the LRP-1-mediated pathway to cross the blood-brain barrier for treating neurological disorders. These new compounds have the potential to address significant unmet medical needs, many of which are insurmountable due to fundamental physiological challenges posed by the blood-brain barrier. Angiochem is developing a focused pipeline including small molecules and biologics for the potential treatment of a wide range of central nervous system diseases, including primary brain cancer, brain metastases, lysosomal storage disorders, and pain. Founded in 2003, Angiochem is headquartered in Montreal, Canada.